The global Cevimeline market size is predicted to grow from US$ 133 million in 2025 to US$ 173 million in 2031; it is expected to grow at a CAGR of 4.4% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Cevimeline is used to treat the symptoms of dry mouth in patients with Sjogrens syndrome (a condition that affects the immune system and causes dryness of certain parts of the body such as the eyes and mouth). Cevimeline is in a class of medications called cholinergic agonists. It works by increasing the amount of saliva in the mouth.

The global Cevimeline market is experiencing moderate growth, primarily driven by the increasing prevalence of Sjgrens syndrome and other autoimmune disorders that lead to dry mouth (xerostomia). Cevimeline, a muscarinic receptor agonist, is primarily used to stimulate saliva production, providing relief to patients suffering from chronic dry mouth conditions. With growing awareness of Sjgrens syndrome and advancements in diagnostic capabilities, more patients are being identified and seeking treatment, which drives market demand. North America dominates the market due to higher diagnosis rates, advanced healthcare infrastructure, and the presence of major pharmaceutical companies. Europe also holds a significant share, while the Asia-Pacific region shows promising growth potential due to improving healthcare facilities, increasing healthcare awareness, and a rising patient population. However, the market faces challenges such as potential side effects of Cevimeline, including excessive sweating, nausea, and blurred vision, which may limit its use among certain patient groups. Additionally, the emergence of alternative therapies and natural treatments may pose a threat to market expansion. Key players are focusing on expanding their product portfolios, obtaining regulatory approvals, and investing in clinical research to explore broader indications for Cevimeline. Collaborations and partnerships for research and distribution are also observed to strengthen market positioning. As healthcare awareness increases and diagnostic technologies advance, the Cevimeline market is expected to grow steadily, though the development of more effective and safer treatment options may influence its long-term trajectory.

Infinity Market Research newest research report, the Cevimeline Industry Forecast looks at past sales and reviews total world Cevimeline sales in 2024, providing a comprehensive analysis by region and market sector of projected Cevimeline sales for 2025 through 2031. With Cevimeline sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cevimeline industry.

This Insight Report provides a comprehensive analysis of the global Cevimeline landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cevimeline portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Cevimeline market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cevimeline and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cevimeline.

This report presents a comprehensive overview, market shares, and growth opportunities of Cevimeline market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    NDA
    ANDA

Segmentation by Application:

    Hospitals
    Clinics
    Retail Pharmacies

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Daiichi Sankyo
    Lupin
    Aurobindo Pharma
    Rubicon Research
    Cosette Pharmaceuticals
    Hikma Pharmaceuticals
    Bionpharma Inc
    Rising Pharma Holdings, Inc.
    Macleods Pharmaceuticals Limited
    Bryant Ranch Prepack

Key Questions Addressed in this Report

What is the 10-year outlook for the global Cevimeline market?
What factors are driving Cevimeline market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cevimeline market opportunities vary by end market size?
How does Cevimeline break out by Type, by Application?